Antibody-Fcγ receptor-driven NOX2 activation during phagocytosis of tumor cells is suppressed by CD47, preventing CD8 T cell engagement and immunotherapeutic responses.
Antibody-dependent cellular phagocytosis (ADCP) contributes to the elimination of antibody-opsonized tumor cells and engagement of adaptive immunity. This process is inhibited by tumor-cell overexpression of CD47. Here, genome-wide CRISPR screens in macrophages identified the NADPH oxidase (NOX2 complex) and the CD47 receptor, SIRPα, as regulators of phagosome acidification. Target-cell CD47 suppressed NOX2 generation of reactive oxygen species at antibody densities that support ADCP, revealing distinct CD47-dependent thresholds for ADCP and oxidant generation. CD47 removal from the target cell delayed phagosome acidification in wild-type macrophages, but not in NOX2-deficient macrophages. Consistent with a role for this pathway in antitumor immunity, tumor-opsonizing anti-Tyrp1 therapy allowed clearance of CD47-deficient B16F10 melanoma tumors in approximately 36% of wild-type mice but failed in NOX2-deficient mice. Tumor clearance required CD8 T cells and IFNγ, but perforin was dispensable. CD4 T cell depletion markedly improved tumor clearance. These findings suggest a noncanonical role for CD8 T cells in supporting ADCP-mediated tumor control. Combining anti-Tyrp1 with a mouse-serum-albumin-IL-2 fusion (MSA-IL-2) or PD-1 blockade enabled superior clearance of CD47-deficient tumors in NOX2-deficient mice, but not wild-type mice. Rechallenge experiments distinguished primary tumor clearance from durable immunity, whereby NOX2-deficient mice treated with anti-Tyrp1 and PD-1 blockade lacked rechallenge protection despite high initial cure rates. Conversely, the addition of MSA-IL-2 supported durable protection in both wild-type and NOX2-deficient mice. These results indicate that tumor CD47 functions beyond a "don't-eat-me" signal by controlling NOX2 activity to positively and negatively regulate CD 8 T cell function. Significance CD47-SIRPα suppresses NOX2 activation, regulating a critical feedback loop between ADCP and CD8 T cell activation during tumor-opsonizing antibody therapy, suggesting new strategies for cancer immunotherapy targeting tumor surface antigens.
Authors
- Adam D. Hoppe (ORCID: https://orcid.org/0000-0003-4180-0840)
- Stephen M. Thirdborough (ORCID: https://orcid.org/0000-0002-6061-0527)
- Natalie W. Thiex (ORCID: https://orcid.org/0000-0001-7028-094X)
- Seuly Akter
- Stephen A. Beers (ORCID: https://orcid.org/0000-0002-3765-3342)
- Mark Steven Cragg (ORCID: https://orcid.org/0000-0003-2077-089X)
- Jason G. Kerkvliet (ORCID: https://orcid.org/0009-0002-8755-4059)
- Jadyn Leek (ORCID: https://orcid.org/0009-0001-8346-2934)
- Pratibha Sharma (ORCID: https://orcid.org/0009-0007-8645-9654)
- Lauren J. Olson (ORCID: https://orcid.org/0009-0008-1586-8095)
- Esme J.C. Fowkes (ORCID: https://orcid.org/0009-0003-4913-1167)
- Hallie M. Kueter
Institutions
- South Dakota State University (US)
- University of Southampton (GB)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.64898/2026.11.19.767930
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- preprint
Funders
- South Dakota State University
- Cancer Research UK
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases